GGrantIndex
← Leaderboards

John Paul Clancy

University Of Alabama At Birmingham

$7,228,581
Attributed
$9,263,271
Total exposure
26
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY200522
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$15,040,650 · 27

By mechanism

P30$8,797,050 · 5
R01$4,671,436 · 3
UG3$636,000 · 1
R21$437,250 · 1
T35$352,450 · 1
M01$146,464 · 16

Top collaborators

Most similar at University Of Alabama At Birmingham

Same institution · by research overlap

Others in their field

Top investigators on “Cystic Fibrosis

Research focus

Cystic FibrosisResearch PersonnelCystic Fibrosis PatientsLungCystic Fibrosis Transmembrane Conductance RegulatorClinical ResearchBaseLung DiseasesMonitorEpithelial CellsCellsMutationNoseTissuesFoundationsFundingInfectionMeasurementInflammationGrantHuman SubjectMedical CenterDesignMethodology

Grant awards (59)

Personalized Cystic Fibrosis Therapy and Research Center$1,137,847
P30 · FY2022 · DK
Clinical Core$232,636
P30 · FY2022 · DK · contact PI
Core-003$229,274
P30 · FY2022 · DK
Personalized Cystic Fibrosis Therapy and Research Center$1,144,093
P30 · FY2021 · DK
Clinical Core$236,087
P30 · FY2021 · DK · contact PI
Core-003$231,301
P30 · FY2021 · DK
Personalized Cystic Fibrosis Therapy and Research Center$1,158,088
P30 · FY2020 · DK
Clinical Core$246,094
P30 · FY2020 · DK · contact PI
Core-003$233,598
P30 · FY2020 · DK
Cincinnati Children's Summer Medical Student Respiratory Research Fellowship$71,920
T35 · FY2020 · HL
Personalized Cystic Fibrosis Therapy and Research Center$1,163,071
P30 · FY2019 · DK
Preclinical characterization of saracatinib for cystic fibrosis therapy$318,000
UG3 · FY2019 · TR
Clinical Core$249,772
P30 · FY2019 · DK · contact PI
Cincinnati Children's Summer Medical Student Respiratory Research Fellowship$71,766
T35 · FY2019 · HL
Personalized Cystic Fibrosis Therapy and Research Center$1,174,280
P30 · FY2018 · DK
Preclinical characterization of saracatinib for cystic fibrosis therapy$318,000
UG3 · FY2018 · TR
Clinical Core$249,772
P30 · FY2018 · DK · contact PI
Targeting Vector Interactome to Enhance CFTR Delivery$198,750
R21 · FY2018 · EB
Cincinnati Children's Summer Medical Student Respiratory Research Fellowship$70,659
T35 · FY2018 · HL
UTE MRI to monitor CF lung disease and response to CFTR modulation in young children$745,633
R01 · FY2017 · HL
Targeting Vector Interactome to Enhance CFTR Delivery$238,500
R21 · FY2017 · EB
Cincinnati Children's Summer Medical Student Respiratory Research Fellowship$69,579
T35 · FY2017 · HL
UTE MRI to monitor CF lung disease and response to CFTR modulation in young children$760,483
R01 · FY2016 · HL
Cincinnati Children's Summer Medical Student Respiratory Research Fellowship$68,526
T35 · FY2016 · HL
MR predictors of infection, inflammation, and structural lung damage in CF$482,554
R01 · FY2015 · HL · contact PI
MR predictors of infection, inflammation, and structural lung damage in CF$536,686
R01 · FY2014 · HL · contact PI
MR predictors of infection, inflammation, and structural lung damage in CF$537,304
R01 · FY2013 · HL · contact PI
MR predictors of infection, inflammation, and structural lung damage in CF$588,376
R01 · FY2012 · HL · contact PI
Clinical Core$145,824
P30 · FY2011 · DK · contact PI
Clinical Core$145,824
P30 · FY2010 · DK · contact PI
Clinical Core$157,088
P30 · FY2009 · DK · contact PI
Clinical Core$133,545
P30 · FY2008 · DK · contact PI
Clinical Core$133,541
P30 · FY2007 · DK · contact PI
EUR-1008-M$14,947
M01 · FY2007 · RR · contact PI
PTC$13,009
M01 · FY2007 · RR · contact PI
LONG-TERM CONTINUATION STUDY OF PATIENTS WITH INFANTILE-ONSET POMPE DISEASE$2,215
M01 · FY2007 · RR · contact PI
MYOZYME IN PATIENTS WITH INFANTILE-ONSET POMPE DISEASE$1,937
M01 · FY2007 · RR · contact PI
PHASE 3 STUDY EVALUATING AZTREONAM LYSIANTE FOR INHALATION IN CYSTIC FIBROSIS$554
M01 · FY2007 · RR · contact PI
EUR-1009-M$554
M01 · FY2007 · RR · contact PI
PTC$18,565
M01 · FY2006 · RR · contact PI
MYOZYME IN PATIENTS WITH INFANTILE-ONSET POMPE DISEASE$6,110
M01 · FY2006 · RR · contact PI
LONG-TERM CONTINUATION STUDY OF PATIENTS WITH INFANTILE-ONSET POMPE DISEASE$4,935
M01 · FY2006 · RR · contact PI
INDUCED SPUTUM AS A TOOL TO EVALUATE ANTI-INFLAMMATORY AGENTS IN CF PATIENTS$3,525
M01 · FY2006 · RR · contact PI
TREATMENT IN PATIENTS < 6 MONTHS OLD WITH INFANTILE-ONSET POMPE DISEASE (1602)$1,645
M01 · FY2006 · RR · contact PI
ORAL THERACLEC TM-TOTAL IN CF SUBJECTS WITH EXOCRINE PANCREATIC INSUFFICIENCY$29,229
M01 · FY2005 · RR
A MULTICENTER, PHASE II STUDY OF AEROSOLIZED TGAAVCF FOR THE TREATMENT OF CF$11,492
M01 · FY2005 · RR
MYOZYME IN PATIENTS WITH INFANTILE-ONSET POMPE DISEASE$6,496
M01 · FY2005 · RR
INDUCED SPUTUM AS A TOOL TO EVALUATE ANTI-INFLAMMATORY AGENTS IN CF PATIENTS$1,499
M01 · FY2005 · RR
POMPE 1602$1,249
M01 · FY2005 · RR
Regulation of CFTR by adenosine, A2 receptors, and PLA2$248,748
R01 · FY2004 · HL
Open-Label Safety and Tolerability Study of TheraCLEC$16,050
M01 · FY2004 · RR
Ph. II Study of Aerosolized tgAAVCF for Treatment of CF$9,132
M01 · FY2004 · RR
Nebulized Aztreonam in CF Patients$3,321
M01 · FY2004 · RR
Regulation of CFTR by adenosine, A2 receptors, and PLA2$248,817
R01 · FY2003 · HL
Regulation of CFTR by adenosine, A2 receptors, and PLA2$248,885
R01 · FY2002 · HL
PILOT--PSEUDOVIRION VECTORS FOR CFTR DELIVERY$165,355
P30 · FY2002 · DK
Regulation of CFTR by adenosine, A2 receptors, and PLA2$273,950
R01 · FY2001 · HL
PILOT--PSEUDOVIRION VECTORS FOR CFTR DELIVERY$165,355
P30 · FY2001 · DK
PILOT--PSEUDOVIRION VECTORS FOR CFTR DELIVERY$64,605
P30 · FY2000 · DK